In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 0.95 below Evoke Pharma Inc average.

Within Major Pharmaceutical Preparations industry 353 other companies have achieved higher Quick Ratio than Evoke Pharma Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 1426 to 1717.

Explain Quick Ratio?
How much Cash & cash equivalents EVOK�s has?
What are EVOK�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EVOK/financial-strength

https://api.csimarket.com/api/v1/companies/EVOK/fundamentals

https://api.csimarket.com/api/v1/companies/EVOK/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

EVOK Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	25.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	2.09 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.95	Subscribe	Subscribe	Subscribe	Subscribe
EVOK's Total Ranking	# 1717	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	5.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-4.01 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 354
Healthcare Sector	# 634
Overall Market	# 1717

Quick Ratio Statistics
High	Average	Low
12.9	4.55	0.59
(Mar 31 2017)		(Dec 31 2023)

Financial Statements
Evoke Pharma Inc 's Current Liabilities	$ 12 Millions	Visit EVOK's Balance sheet
Evoke Pharma Inc 's Cash & cash equivalent	$ 12 Millions	Visit EVOK's Balance sheet
Source of EVOK's Sales		Visit EVOK's Sales by Geography

Cumulative Evoke Pharma Inc 's Quick Ratio

EVOK's Quick Ratio for the trailling 12 Months

EVOK Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	13.14 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	42.61 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.12	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3176	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	0.48 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to EVOK Financial Strength Comparisons >> Go to Compare EVOK Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2025 to $12.24 millions, cumulative Quick Ratio decreased to 1.12 below the Evoke Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 412 other companies have achieved higher Quick Ratio than Evoke Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 3000 to 3176.

Explain Quick Ratio?
How much Cash & cash equivalents EVOK�s has?
What are EVOK�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 413
Healthcare Sector	# 858
Within the Market	# 3176

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.53	3.25	0.92
(Jun 30 2022)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Universe Pharmaceuticals Inc	2.55	$ 33,592.025 Millions	$ 13,173.930 Millions
Elite Pharmaceuticals Inc	2.51	$ 26.765 Millions	$ 10.674 Millions
Ionis Pharmaceuticals Inc	2.48	$ 2,240.171 Millions	$ 903.456 Millions
Corcept Therapeutics Inc	2.45	$ 421.683 Millions	$ 172.265 Millions
Acurx Pharmaceuticals inc	2.39	$ 5.907 Millions	$ 2.468 Millions
Mannkind Corporation	2.38	$ 260.035 Millions	$ 109.130 Millions
Acadia Pharmaceuticals Inc	2.38	$ 847.019 Millions	$ 356.584 Millions
Greenwich Lifesciences Inc	2.35	$ 3.807 Millions	$ 1.622 Millions
Alkermes Plc	2.34	$ 1,111.114 Millions	$ 474.360 Millions
Mirum Pharmaceuticals Inc	2.34	$ 375.548 Millions	$ 160.359 Millions
Verastem Inc	2.31	$ 137.706 Millions	$ 59.712 Millions
Biohaven Ltd	2.30	$ 260.217 Millions	$ 113.023 Millions
Pacira Biosciences inc	2.30	$ 246.334 Millions	$ 107.078 Millions
Wave Life Sciences Ltd	2.28	$ 196.218 Millions	$ 85.896 Millions
Filana Therapeutics Inc	2.27	$ 106.080 Millions	$ 46.680 Millions
Oculis Holding Ag	2.21	$ 102.481 Millions	$ 46.304 Millions
Petros Pharmaceuticals inc	2.20	$ 6.070 Millions	$ 2.765 Millions
Alx Oncology Holdings Inc	2.19	$ 60.626 Millions	$ 27.722 Millions
Gain Therapeutics inc	2.18	$ 8.807 Millions	$ 4.043 Millions
Regeneron Pharmaceuticals Inc	2.18	$ 8,443.600 Millions	$ 3,879.500 Millions
Transcode Therapeutics Inc	2.14	$ 5.923 Millions	$ 2.772 Millions
Seres Therapeutics Inc	2.12	$ 47.638 Millions	$ 22.429 Millions
Foghorn Therapeutics Inc	2.12	$ 180.278 Millions	$ 85.088 Millions
Alaunos Therapeutics Inc	2.10	$ 1.938 Millions	$ 0.921 Millions
Atrium Therapeutics Inc	2.06	$ 350.158 Millions	$ 169.879 Millions
Scisparc Ltd	2.04	$ 4.591 Millions	$ 2.253 Millions
Hyperion Defi inc	2.04	$ 8.223 Millions	$ 4.037 Millions
Veru Inc	2.03	$ 15.795 Millions	$ 7.785 Millions
Mustang Bio inc	2.01	$ 18.984 Millions	$ 9.440 Millions
Nasus Pharma Ltd	1.98	$ 4.286 Millions	$ 2.163 Millions

Date modified: 2026-10-05T11:03:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.